Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question

Apr 24 2017

• By Jessica Merrill

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

Related Content

First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib

Feb 04 2015

Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?

Mar 21 2017

Novartis Sets 'Flexible Pricing' For Kisqali To Compete Against Pfizer's Ibrance

Mar 14 2017

Related Companies

Eli Lilly and Company

Pfizer Inc.

Novartis AG

Additional Topics

Clinical Trials Commercial Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.